A new era in liquid biopsy testing
FDA-approved Guardant360 Liquid CDx powered by InfinityAI
is the largest FDA-approved panel enabling deeper
understanding of tumor biology to help guide more
informed treatment decisions.
Covers 740+ genes
and is the first to
unlock epigenomics1,2*
Home Screening MRD + Monitoring Treatment Selection
Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant360 Liquid is not approved nor marketed in EU.
High sensitivity
Variants detected as low as
0.001% MAF1
MAF, mutant allele fraction.
*Guardant360 Liquid is the first and only commercially available liquid biopsy to unlock genomics and epigenomics from a single input.
†Median turnaround time from sample receipt to results.
Fast results
in 7 days1†
Infinity-powered
epigenomics & genomics